➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Medtronic
Moodys
Dow
AstraZeneca

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Anifrolumab


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Anifrolumab?

Anifrolumab is an investigational drug.

There have been 7 clinical trials for Anifrolumab. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2015.

The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Lupus Nephritis, and Arthritis, Rheumatoid. The leading clinical trial sponsors are AstraZeneca, PRA Health Sciences, and Josef Smolen, Univ. Prof. Dr.

There are four US patents protecting this investigational drug and twenty-four international patents.

Recent Clinical Trials for Anifrolumab
TitleSponsorPhase
A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)Josef Smolen, Univ. Prof. Dr.Phase 2
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin ManifestationsAstraZenecaPhase 2
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus ErythematosusPRA Health SciencesPhase 3

See all Anifrolumab clinical trials

Clinical Trial Summary for Anifrolumab

Top disease conditions for Anifrolumab
Top clinical trial sponsors for Anifrolumab

See all Anifrolumab clinical trials

US Patents for Anifrolumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Anifrolumab   Start Trial Stable anti-IFNAR1 formulation AstraZeneca AB (Sodertalje, SE)   Start Trial
Anifrolumab   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
Anifrolumab   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
Anifrolumab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Anifrolumab

Drugname Country Document Number Estimated Expiration Related US Patent
Anifrolumab Australia 2016308262 2035-08-19   Start Trial
Anifrolumab Brazil 112018002196 2035-08-19   Start Trial
Anifrolumab Canada 2995222 2035-08-19   Start Trial
Anifrolumab China 107921109 2035-08-19   Start Trial
Anifrolumab European Patent Office 3337502 2035-08-19   Start Trial
Anifrolumab Israel 257279 2035-08-19   Start Trial
Anifrolumab Japan 2018523676 2035-08-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Baxter
McKinsey
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.